TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19914605

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the nucleus accumbens (NAcc)
Number of subjects: 10
Study: 19915292

Group type: EXPERIMENTAL
Intervention: 200 mg/day of etidronate cyclically
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-dose glucocorticoids (GCs)
Number of subjects: 44
Study: 19915602

Group type: EXPERIMENTAL
Intervention: Multicenter clinical trials in pediatric oncology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neonatology intensive care units (NICUs)
Number of subjects: 0
Study: 19915888

Group type: EXPERIMENTAL
Intervention: Fontan patients undergoing CPET
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 38
Study: 19916704

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 171
Study: 19916705

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 21729

Group type: EXPERIMENTAL
Intervention: BIAsp 30 (treatment-naïve subgroup)
Number of subjects: 21729

Group type: EXPERIMENTAL
Intervention: BIAsp 30 (OADs only subgroup)
Number of subjects: 21729

Group type: EXPERIMENTAL
Intervention: BIAsp 30 (insulin +/- OADs subgroup)
Number of subjects: 21729
Study: 19917888

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 19918104

Group type: EXPERIMENTAL
Intervention: Generic lopinavir/ritonavir 200/50 mg tablet formulation (400/100 mg twice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Kaletra(R) soft-gel capsules
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Generic ritonavir
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Generic lopinavir/ritonavir tablet
Number of subjects: 37
Study: 19920002

Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Insulin provision
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 2005
Study: 19920114

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg twice daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dasatinib (both dosages)
Number of subjects: 47
Study: 19920819

Group type: EXPERIMENTAL
Intervention: Bevacizumab with metronomic etoposide (10 mg kg(-1) bevacizumab biweekly and 50 mg m(-2) etoposide daily for 21 consecutive days each month)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bevacizumab with metronomic etoposide
Number of subjects: 59
Study: 19922035

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention 'Obeldicks'
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Baseline leptin concentrations
Number of subjects: 248
Study: 19922036

Group type: EXPERIMENTAL
Intervention: Active recruitment methods (pediatrician referral and targeted mailings)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Passive recruitment methods
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pediatrician referral
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Overall recruitment costs
Number of subjects: 164
Study: 19922631

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 100
Study: 19923206

Group type: EXPERIMENTAL
Intervention: Workshops to improve supervision frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervision process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support from leaders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research on supervision strategies
Number of subjects: 0
Study: 19923368

Group type: EXPERIMENTAL
Intervention: DHA intake
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: EPA intake
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) intake
Number of subjects: 105
Study: 19923369

Group type: EXPERIMENTAL
Intervention: PUFA intake
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SFA intake
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MUFA intake
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ex vivo incubation with different fatty acids
Number of subjects: 21
Study: 19923375

Group type: EXPERIMENTAL
Intervention: 1 mg folate/d
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 19923376

Group type: EXPERIMENTAL
Intervention: Computerized vending machine system
Number of subjects: 12
Study: 19923475

Group type: EXPERIMENTAL
Intervention: Monotherapy with isoniazid, gatifloxicin, levofloxacin, and moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin-based regimen
Number of subjects: 0
Study: 19926602

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (CES-D score >or=16)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms (CES-D score >or=24)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Primary endpoint (death or readmission for HF)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: CES-D score
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms
Number of subjects: 958
Study: 19929182

Group type: EXPERIMENTAL
Intervention: Consultation with GP every three months
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Prescription redemption for ACE inhibitor or angiotensin-II receptor antagonist
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: High initial BP
Number of subjects: 361
Study: 19929434

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 microg/day subcutaneously
Number of subjects: 10
Study: 19930156

Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine combined with gemcitabine (1000 mg/m² on days 1, 8, and 15 in a 28-day cycle)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine combined with gemcitabine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine
Number of subjects: 18
Study: 19930599

Group type: EXPERIMENTAL
Intervention: Nedaplatin (10 mg/body/day) and 5-FU (500 mg/body/day) with radiation (50.4-66 Gy)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nedaplatin and 5-FU with radiation
Number of subjects: 33
Study: 19931137

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² IV and oxaliplatin 130 mg/m² IV every 21 days
Number of subjects: 32
Study: 19932054

Group type: EXPERIMENTAL
Intervention: GEMOX-B (bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2), oxaliplatin 85 mg/m(2))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GEMOX-B
Number of subjects: 35
Study: 19932729

Group type: EXPERIMENTAL
Intervention: 14.6 g cis-9,trans-11 CLA and 4.7 g trans-10,cis-12 CLA isomers daily for 3 weeks
Number of subjects: 20
Study: 19933192

Group type: COMPARATOR
Intervention: Ocular ischemic syndrome (OIS)
Number of subjects: 13
Study: 19933938

Group type: EXPERIMENTAL
Intervention: HeartMate II continuous-flow left ventricular assist device
Number of subjects: 309
Study: 19933939

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study: 19933994

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg daily) plus folic acid (400 microg daily), n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 50
Study: 19936297

Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin for scabies treatment and referral for pyoderma treatment according to guidelines.
Number of subjects: 2329

Group type: EXPERIMENTAL
Intervention: Annual mass scabies treatment with 5% permethrin cream offered to all community residents.
Number of subjects: 2329
Study: 19937992

Group type: EXPERIMENTAL
Intervention: MIGTS
Number of subjects: 168
Study: 19939200

Group type: EXPERIMENTAL
Intervention: Plasma human HGF (hHGF) concentrations assessed at admission and 24 hours later
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: hHGF levels in STEMI patients
Number of subjects: 104
Study: 19940224

Group type: EXPERIMENTAL
Intervention: Hypoglycemia-related driving mishaps
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Driving mishaps
Number of subjects: 452
Study: 19940961

Group type: EXPERIMENTAL
Intervention: Mobile phone-based structured intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 19946370

Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered immediately (same day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered early (next day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered delayed (7 days)
Number of subjects: 323
Study: 19946371

Group type: EXPERIMENTAL
Intervention: Immediate testing (same day, n = 103)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Early testing (next day, n = 98)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Delayed testing (7 days, n = 97)
Number of subjects: 298
Study: 19946413

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/day and 300 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 22
Study: 19948045

Group type: EXPERIMENTAL
Intervention: Bispectral index-guided anesthesia (target range, 40 to 60)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: End-tidal anesthetic gas-guided anesthesia (target range, 0.7 to 1.3 age-adjusted minimum alveolar concentration)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Bispectral index-guided anesthesia
Number of subjects: 6000

Group type: COMPARATOR
Intervention: End-tidal anesthetic gas-guided anesthesia
Number of subjects: 6000
Study: 19950084

Group type: EXPERIMENTAL
Intervention: Elective heart transplantation (HTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medically treated patients with heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with severe heart failure (NYHA class IV)
Number of subjects: 0
Study: 19951974

Group type: EXPERIMENTAL
Intervention: Flow cytometric monitoring of candidate leukemic stem cells (LSC) defined by the immunophenotype CD34+CD38lowCD19+
Number of subjects: 48
Study: 19952143

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine
Number of subjects: 797

Group type: COMPARATOR
Intervention: Tenofovir DF-emtricitabine
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 797
Study: 19953376

Group type: EXPERIMENTAL
Intervention: Best possible invasive therapy (endovascular, neurosurgical, and/or radiation therapy)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Medical management without intervention
Number of subjects: 800
Study: 19953837

Group type: EXPERIMENTAL
Intervention: Participation in sports teams
Number of subjects: 717
Study: 19954265

Group type: EXPERIMENTAL
Intervention: Q2W darbepoetin alfa
Number of subjects: 104
Study: 19955104

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 204
Study: 19955196

Group type: EXPERIMENTAL
Intervention: High-dose 9-cis-beta-carotene (four capsules daily for 90 days)
Number of subjects: 7
Study: 19956459

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg once daily
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg once daily
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Quetiapine (both doses)
Number of subjects: 1051
Study: 19958862

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 1373
Study: 19959119

Group type: EXPERIMENTAL
Intervention: ICD implantation (63.8%) or CRT with defibrillator (36.2%)
Number of subjects: 15221
Study: 19959652

Group type: EXPERIMENTAL
Intervention: Cervical and thoracic spine manipulation (thrust and nonthrust manipulations)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cervical and thoracic spine manipulation
Number of subjects: 80
Study: 19962985

Group type: EXPERIMENTAL
Intervention: High-dose insulin (264.3 +/- 25 mU/L)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 29
Study: 19963351

Group type: EXPERIMENTAL
Intervention: Nutritional support (enteral nutrition)
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Nutritional support (parenteral nutrition)
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Nutritional support (overall)
Number of subjects: 1831

Group type: COMPARATOR
Intervention: No nutritional support
Number of subjects: 1831
Study: 19965642

Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 0
Study: 19965657

Group type: EXPERIMENTAL
Intervention: Busulfan conditioning and MFGS retroviral vector encoding gp91(phox)
Number of subjects: 3
Study: 19965662

Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium 200 mg twice daily
Number of subjects: 68
Study: 19995118

Group type: EXPERIMENTAL
Intervention: Pathway PV System
Number of subjects: 172
Study: 19995432

Group type: EXPERIMENTAL
Intervention: Mismatch concept in acute stroke treatment using perfusion imaging (PI) with a fixed dosage of 5 ml 1 M Gadobutrol.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Mismatch concept in acute stroke treatment using perfusion imaging (PI).
Number of subjects: 1200
Study: 19995444

Group type: EXPERIMENTAL
Intervention: NIR treatment to left forehead (F3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NIR treatment to right forehead (F4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NIR treatment (on condition)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment (light off)
Number of subjects: 10
Study: 19996412

Group type: EXPERIMENTAL
Intervention: Deferasirox (mean dose 32.6 mg/kg per day) in the cardiac iron reduction arm
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (prevention arm)
Number of subjects: 192
Study: 19996872

Group type: EXPERIMENTAL
Intervention: Estrogen-containing hormone therapy after the age of 60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen therapy in middle-aged women before the age of 60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogens after surgical menopause
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural menopause transition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy initiation in old age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midlife estrogen therapy
Number of subjects: 0
Study: 19996998

Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor endurance training for 6 weeks in HC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor endurance training for 6 weeks in CHF
Number of subjects: 24
Study: 20001658

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs (LLD) for >3 months (stable medication >6 weeks)
Number of subjects: 14478

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 14478

Group type: EXPERIMENTAL
Intervention: Good treatment adherence
Number of subjects: 14478

Group type: EXPERIMENTAL
Intervention: Normal body mass index
Number of subjects: 14478

Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 14478

Group type: EXPERIMENTAL
Intervention: Not having metabolic syndrome
Number of subjects: 14478
Study: 20001856

Group type: EXPERIMENTAL
Intervention: Enfuvirtide-containing therapy (including 2 reverse-transcriptase inhibitors and a ritonavir-boosted protease inhibitor) for at least 48 weeks
Number of subjects: 19
Study: 20003108

Group type: EXPERIMENTAL
Intervention: Foveal thickness measured by optical coherence tomography (OCT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Microperimetry measurements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cystoid changes in the outer plexiform and inner nuclear layer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Presence of epiretinal membrane
Number of subjects: 31
Study: 20003260

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 171
Study: 20003269

Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (400 mg bid)
Number of subjects: 28
Study: 20003457

Group type: EXPERIMENTAL
Intervention: TPV/r-based cART
Number of subjects: 1299
Study: 20003507

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 56
Study: 20003832

Group type: EXPERIMENTAL
Intervention: Pegvisomant, administered as daily subcutaneous injections adjusted according to IGF-I levels.
Number of subjects: 19
Study: 20004787

Group type: EXPERIMENTAL
Intervention: IL-5+ T(H)2 cells in AEG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 cells in AEG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-5+ T(H)2 cells for all foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 responses to peanut in PA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 responses to peanut in AEG
Number of subjects: 0

Group type: COMPARATOR
Intervention: T(H)1 responses to food antigens
Number of subjects: 0
Study: 20007560

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by G-CSF, with 300 cGy total-body irradiation plus alemtuzumab before transplantation and sirolimus afterward
Number of subjects: 10
Study: 20007664

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16
Study: 20007792

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in renal patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(-1) in renal patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in healthy controls
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg(-1) in healthy controls
Number of subjects: 15
Study: 20007809

Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase (2500 IU/m²) administered over 1 hour during remission induction
Number of subjects: 197
Study: 20008298

Group type: EXPERIMENTAL
Intervention: CEP-701 (80 mg orally twice daily)
Number of subjects: 22
Study: 20008626

Group type: EXPERIMENTAL
Intervention: Romiplostim 300 microg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Romiplostim 700 microg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Romiplostim 1,000 microg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Romiplostim 1,500 microg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 44
Study: 20008941

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (36 sessions)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 69
Study: 20009044

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 4685

Group type: COMPARATOR
Intervention: No ICD
Number of subjects: 4685
Study: 20009522

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Number of subjects: 403
Study: 20009777

Group type: EXPERIMENTAL
Intervention: Quality improvement interventions by physicians
Number of subjects: 974
Study: 20010088

Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 86
Study: 20010317

Group type: EXPERIMENTAL
Intervention: Matrilineal relatives (with the same mtDNA sequence as the proband)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Nonmatrilineal relatives (with another mtDNA sequence)
Number of subjects: 672
Study: 20012045

Group type: EXPERIMENTAL
Intervention: VTD (Bortezomib, Thalidomide, Dexamethasone) followed by MPT (Melphalan, Prednisolone, Thalidomide)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: VTD followed by MPT
Number of subjects: 35
Study: 20014952

Group type: EXPERIMENTAL
Intervention: 25 mg/kg valacyclovir oral suspension (single dose)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 10 mg/kg valacyclovir oral suspension (twice daily for 3-5 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 20 mg/kg valacyclovir oral suspension (3 times daily for 5 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Valacyclovir oral suspension (various dosages)
Number of subjects: 112
Study: 20015886

Group type: EXPERIMENTAL
Intervention: escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) combined with intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: escalated imatinib and intravenous cytarabine
Number of subjects: 162
Study: 20016847

Group type: EXPERIMENTAL
Intervention: Leishmanin skin test (LST) in Kemena
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leishmanin skin test (LST) in Sougoula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual incidence of Leishmania infection in Kemena (2007)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual incidence of Leishmania infection in Kemena (2008)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual incidence of Leishmania infection in Sougoula (2007)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual incidence of Leishmania infection in Sougoula (2008)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk of Leishmania infection in Kemena (2007)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk of Leishmania infection in Kemena (2008)
Number of subjects: 0
Study: 20018280

Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope (TER)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: TER for lesions 6 mm or larger
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: TER for lesions 10 mm or larger
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: TER
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: TER in the left colon
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: TER in the right colon
Number of subjects: 249
Study: 20018959

Group type: EXPERIMENTAL
Intervention: Minor allele (G) of MMP12 SNP (rs2276109)
Number of subjects: 8300
Study: 20019013

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) monitoring
Number of subjects: 26
Study: 20019294

Group type: EXPERIMENTAL
Intervention: HIV prevention interventions
Number of subjects: 0
Study: 20022127

Group type: EXPERIMENTAL
Intervention: SEVEN(R) CGM system
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Navigator(R) CGM system
Number of subjects: 14